EnCor and SenoRx breast tissue biopsy markers have previously received regulatory clearances from China’s State Food & Drug Administration and from countries within the European Economic Community and from all other countries that SenoRx has established distribution channels.
Lloyd Malchow, SenoRx’s president and CEO, said: “We are excited to enter the China market, which represents a continuation of our efforts to expand our international footprint in key markets where breast-care is increasingly becoming a national healthcare priority.
“China remains one of the fastest growing economies in the world and has been devoting an increasing percentage of its gross domestic product on improving healthcare for its people. Increasing awareness and detection of breast cancer in China has created a growing market for the latest minimally invasive vacuum-assisted breast biopsy technology.”